[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1174914A1 - Cgrp receptor antagonist cgrp - Google Patents

Cgrp receptor antagonist cgrp

Info

Publication number
HK1174914A1
HK1174914A1 HK13102079.5A HK13102079A HK1174914A1 HK 1174914 A1 HK1174914 A1 HK 1174914A1 HK 13102079 A HK13102079 A HK 13102079A HK 1174914 A1 HK1174914 A1 HK 1174914A1
Authority
HK
Hong Kong
Prior art keywords
cgrp
receptor antagonist
cgrp receptor
antagonist cgrp
antagonist
Prior art date
Application number
HK13102079.5A
Other languages
Chinese (zh)
Inventor
V Chaturvedula Prasad
M Dubowchik Gene
E Macor John
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43896902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1174914(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HK1174914A1 publication Critical patent/HK1174914A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK13102079.5A 2010-03-30 2013-02-19 Cgrp receptor antagonist cgrp HK1174914A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31901510P 2010-03-30 2010-03-30
PCT/US2011/028168 WO2011123232A1 (en) 2010-03-30 2011-03-11 Cgrp receptor antagonist

Publications (1)

Publication Number Publication Date
HK1174914A1 true HK1174914A1 (en) 2013-06-21

Family

ID=43896902

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13102079.5A HK1174914A1 (en) 2010-03-30 2013-02-19 Cgrp receptor antagonist cgrp

Country Status (30)

Country Link
US (1) US8481546B2 (en)
EP (1) EP2552906B1 (en)
JP (1) JP5908455B2 (en)
KR (3) KR20180049168A (en)
CN (1) CN102834388B (en)
AR (1) AR080746A1 (en)
AU (1) AU2011233627B2 (en)
BR (1) BR112012024785B1 (en)
CA (1) CA2794950C (en)
CL (1) CL2012002739A1 (en)
CY (1) CY1117593T1 (en)
DK (1) DK2552906T3 (en)
EA (1) EA022815B1 (en)
ES (1) ES2562610T3 (en)
HK (1) HK1174914A1 (en)
HR (1) HRP20160287T1 (en)
HU (1) HUE028735T2 (en)
IL (1) IL221665A (en)
MX (1) MX2012010725A (en)
NZ (1) NZ603231A (en)
PE (1) PE20130340A1 (en)
PL (1) PL2552906T3 (en)
PT (1) PT2552906E (en)
RS (1) RS54608B1 (en)
SG (1) SG183918A1 (en)
SI (1) SI2552906T1 (en)
SM (1) SMT201600078B (en)
TW (1) TWI483937B (en)
WO (1) WO2011123232A1 (en)
ZA (1) ZA201207292B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
BR112021005873A2 (en) * 2018-10-13 2021-07-27 Biohaven Pharmaceutical Holding Company Ltd. cgrp antagonist prodrugs
US20210338654A1 (en) * 2019-01-20 2021-11-04 Biohaven Pharmaceutical Holding Company Ltd. Cgrp antagonists for treating migraine breakthrough
MX2021012354A (en) * 2019-04-11 2021-10-22 Scherer Technologies Llc R P Formulation for oral delivery of proteins, peptides and small molecules with poor permeability.
US20220401439A1 (en) * 2019-12-17 2022-12-22 Biohaven Pharmaceutical Holding Company Ltd. Intranasal pharmaceutical compositions of cgrp inhibitors
EP4247364A4 (en) * 2020-11-19 2024-10-23 Pfizer Ireland Pharmaceuticals Compositions for improved delivery of cgrp inhibitors
KR20230157986A (en) 2021-03-02 2023-11-17 체게에르페 다이어그노스틱스 게엠베하 Treating and/or Reducing the Occurrence of Migraine
US20240199578A1 (en) 2021-04-09 2024-06-20 Teva Czech Industries S.R.O Solid state forms of zavegepant and process for preparation thereof
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
WO2024046223A1 (en) * 2022-08-30 2024-03-07 熙源安健医药(上海)有限公司 Indazole formamide derivatives, preparation method therefor, and use thereof
WO2024100599A1 (en) 2022-11-09 2024-05-16 Teva Czech Industries S.R.O. Solid state forms of zavegepant hydrochloride and process for preparation thereof
CN116003387B (en) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 Deuterated indazole propionamide compound, pharmaceutical composition and application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
RS52552B (en) 2002-06-05 2013-04-30 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
EP1722792A1 (en) 2004-03-03 2006-11-22 Boehringer Ingelheim International GmbH Selected cgrp-antagonists, method for the production and use thereof as medicaments
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
CN101495480B (en) * 2006-05-03 2013-07-10 百时美施贵宝公司 Constrained compounds as cgrp-receptor antagonists
WO2010006168A2 (en) 2008-07-09 2010-01-14 University Of Rochester Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor

Also Published As

Publication number Publication date
SI2552906T1 (en) 2016-05-31
EP2552906A1 (en) 2013-02-06
DK2552906T3 (en) 2016-03-29
HRP20160287T1 (en) 2016-04-08
CY1117593T1 (en) 2017-06-28
ES2562610T3 (en) 2016-03-07
US20120059017A1 (en) 2012-03-08
EP2552906B1 (en) 2016-01-06
SMT201600078B (en) 2016-04-29
KR20130076807A (en) 2013-07-08
EA201270751A1 (en) 2013-02-28
KR20180049168A (en) 2018-05-10
PE20130340A1 (en) 2013-03-30
AU2011233627B2 (en) 2013-09-12
CA2794950A1 (en) 2011-10-06
WO2011123232A1 (en) 2011-10-06
TW201139414A (en) 2011-11-16
KR101747477B1 (en) 2017-06-14
PT2552906E (en) 2016-03-18
KR20170068615A (en) 2017-06-19
JP5908455B2 (en) 2016-04-26
BR112012024785A8 (en) 2017-10-17
AU2011233627A1 (en) 2012-11-15
TWI483937B (en) 2015-05-11
CL2012002739A1 (en) 2013-03-22
US8481546B2 (en) 2013-07-09
SG183918A1 (en) 2012-10-30
JP2013523733A (en) 2013-06-17
CA2794950C (en) 2017-09-26
BR112012024785A2 (en) 2016-06-07
IL221665A (en) 2016-07-31
BR112012024785B1 (en) 2020-12-01
PL2552906T3 (en) 2016-06-30
AR080746A1 (en) 2012-05-02
NZ603231A (en) 2014-02-28
RS54608B1 (en) 2016-08-31
ZA201207292B (en) 2014-03-26
EA022815B1 (en) 2016-03-31
CN102834388A (en) 2012-12-19
KR101854249B1 (en) 2018-05-03
MX2012010725A (en) 2012-10-05
CN102834388B (en) 2014-07-16
HUE028735T2 (en) 2017-01-30

Similar Documents

Publication Publication Date Title
HUS2200033I1 (en) CGRP receptor antagonists
HUS2300037I1 (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
PT2927224T (en) Receptor antagonists
HK1174914A1 (en) Cgrp receptor antagonist cgrp
EP2427430A4 (en) 5-oxo-ete receptor antagonist compounds
EP2619204A4 (en) Triazolopyrazinones as p2x7 receptor antagonists
EP2617717A4 (en) P2x4 receptor antagonist
HK1192228A1 (en) Trpm8 receptor antagonists trpm8
EP2627329A4 (en) Trpa1 receptor antagonist
EP2566494A4 (en) Cxcr4 receptor compounds
EP2539706A4 (en) Arylpiperazone opioid receptor antagonists
IL241743A0 (en) Nicotinic receptor non-competitive antagonists
EP2408304A4 (en) Cgrp receptor antagonists
EP2846800A4 (en) Heterocyclic cgrp receptor antagonists
GB0922455D0 (en) Ep2 receptor antagonists
GB201213698D0 (en) Receptor antagonists II
GB201213699D0 (en) Receptor antagonists II